States Step Up Push to Regulate Pharmacy Drug Brokers
(By Katheryn Houghton for Kaiser Health News) Under pressure to rein in skyrocketing prescription drug costs, states are targeting companies
Read More
Part D/Prescription Drugs
Walmart announces the launch of its own analog insulin
Walmart has announced the launch of its private brand of analog insulin through the ReliOn brand. The vials will be
Read MoreMedicare Extra Help
The price for brand-name drugs increased, on average, by 159 percent between 2007 and 2018, according to the latest study
Read MoreMedicare could limit who gets new Alzheimer’s drug
(By Lauren Jensik for Becker’s Hospital Review) Medicare members could face barriers to accessing Biogen’s new Alzheimer’s drug, Aduhelm, due to
Read MoreIf you are still working, should you sign up for Medicare at 65?
Seniors who are still working with employer health insurance when they turn 65 and are confused if they need to
Read MoreWill Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read MoreWhy Drug Price Negotiation Has Staying Power
(By Drew Altman for Kaiser Family Foundation, published June 25, 2021) The fact that prescription drugs represent just 10% of national
Read MoreMedicare spent $2.1B on discarded drugs in 2 years, study shows
(By Katie Adams for Becker’s Hospital Review) More than $2.1 billion of Medicare Part B’s spending from 2017 to 2019 went
Read MorePoint32Health challenges Aduhelm, threatens coverage for 1.1M members
(By Nick Moran for Becker’s Hospital Review) Point32Health may not cover Biogen’s new Alzheimer’s treatment, Aduhelm, for its commercial members unless
Read MoreA crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?
(By Megan Molteni for STAT) For families and physicians grappling with the historic approval this month of the controversial Alzheimer’s
Read More